Annovis Bio Statistics

Total Valuation

Annovis Bio has a market cap or net worth of $40.57 million. The enterprise value is $27.93 million.

Market Cap	40.57M
Enterprise Value	27.93M

Important Dates

The next estimated earnings date is Monday, March 31, 2025, before market open.

Earnings Date	Mar 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Annovis Bio has 19.05 million shares outstanding. The number of shares has increased by 28.48% in one year.

Current Share Class	19.05M
Shares Outstanding	19.05M
Shares Change (YoY)	+28.48%
Shares Change (QoQ)	+14.75%
Owned by Insiders (%)	14.78%
Owned by Institutions (%)	6.98%
Float	15.23M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	4.01
P/TBV Ratio	5.74
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.66

Current Ratio	2.66
Quick Ratio	2.34
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -596.70% and return on invested capital (ROIC) is -276.95%.

Return on Equity (ROE)	-596.70%
Return on Assets (ROA)	-154.58%
Return on Invested Capital (ROIC)	-276.95%
Return on Capital Employed (ROCE)	-338.93%
Revenue Per Employee	n/a
Profits Per Employee	-$2.56M
Employee Count	16
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -78.83% in the last 52 weeks. The beta is 1.63, so Annovis Bio's price volatility has been higher than the market average.

Beta (5Y)	1.63
52-Week Price Change	-78.83%
50-Day Moving Average	4.40
200-Day Moving Average	7.25
Relative Strength Index (RSI)	18.44
Average Volume (20 Days)	684,083

Short Selling Information

The latest short interest is 1.93 million, so 10.11% of the outstanding shares have been sold short.

Short Interest	1.93M
Short Previous Month	1.63M
Short % of Shares Out	10.11%
Short % of Float	12.64%
Short Ratio (days to cover)	4.45

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-30.40M
Pretax Income	-47.53M
Net Income	-40.94M
EBITDA	n/a
EBIT	-30.40M
Earnings Per Share (EPS)	-$3.97

Full Income Statement

Balance Sheet

Cash & Cash Equivalents	12.64M
Total Debt	n/a
Net Cash	12.64M
Net Cash Per Share	$0.66
Equity (Book Value)	7.06M
Book Value Per Share	0.53
Working Capital	8.97M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-22.97M
Capital Expenditures	n/a
Free Cash Flow	-22.97M
FCF Per Share	-$1.21

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Annovis Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-28.48%
Shareholder Yield	-28.48%
Earnings Yield	-100.91%
FCF Yield	-56.63%

Analyst Forecast

The average price target for Annovis Bio is $31.40, which is 1,374.18% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$31.40
Price Target Difference	1,374.18%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1